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Abstract
Purpose Neuroleptic (antipsychotic) drugs reduce psychotic symptoms, but how they achieve these effects and how the 
drugs’ effects are experienced by people who take them are less well understood. The present study describes a synthesis 
of qualitative data about mental and behavioural alterations associated with taking neuroleptics and how these interact with 
symptoms of psychosis and people’s sense of self and agency.
Methods Nine databases were searched to identify qualitative literature concerning experiences of taking neuroleptic medi-
cation. A thematic synthesis was conducted.
Results Neuroleptics were commonly experienced as producing a distinctive state of lethargy, cognitive slowing, emotional 
blunting and reduced motivation, which impaired functioning but also had beneficial effects on symptoms of psychosis 
and some other symptoms (e.g. insomnia). For some people, symptom reduction helped restore a sense of normality and 
autonomy, but others experienced a loss of important aspects of their personality. Across studies, many people adopted a 
passive stance towards long-term medication, expressing a sense of resignation, endurance or loss of autonomy.
Conclusions Neuroleptic drugs modify cognition, emotions and motivation. These effects may be associated with reduc-
ing the intensity and impact of symptoms, but also affect people’s sense of self and agency. Understanding how the effects 
of neuroleptics are experienced by those who take them is important in developing a more collaborative approach to drug 
treatment in psychosis and schizophrenia.
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Introduction
Neuroleptic medication (also known as ‘antipsychotic’ med-
ication) is the primary treatment for people with a diagnosis 
of schizophrenia or other psychotic disorders [1, 2]. There is 
evidence that it reduces acute psychotic symptoms and risk 
of relapse [3]. However, neuroleptics have many adverse 
effects and recent accounts suggest they may be overused 
[4–6]. The action of neuroleptics is thought to be mediated 
through their effects on neurotransmitters, but the manner in 
which they modify symptoms remains uncertain. Early pio-
neers of neuroleptic treatment suggested that the ability of 
neuroleptics to reduce the intensity of emotional responses 
and motivation was relevant to their neuroleptic effects [7, 
8], and this idea has been reiterated more recently [8–10]. 
These effects are also likely to impact on other areas of 
people’s experience, such as their sense of self and agency, 
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including their sense of choice and power over treatment 
decisions. Indeed, research has shown that people’s sense 
of self and agency are affected by the use of other mind-
modifying medicines, such as anti-depressants [11, 12].
Several qualitative studies have been conducted that 
describe the experiences of taking neuroleptics [13]. The 
rich nature of qualitative data means these studies can 
highlight the complex alterations to conscious experience, 
mental functions and behaviour that neuroleptics produce, 
arguably more successfully than quantitative approaches 
(e.g. use of side effect scales). It can also clarify how such 
effects interact with symptoms of psychosis, and how they 
impact on people’s sense of self and agency. The current 
study is a systematic review of the literature that is aimed to 
explore these issues using qualitative methods. Specifically, 
our research addresses the following questions:
1. What does qualitative research indicate about the men-
tal and behavioural alterations produced by neuroleptic 
drugs and how do these impact on symptoms?
2. How do neuroleptics affect people’s sense of self and 
agency?
The first question aims to establish the particular experi-
ences induced by neuroleptic drugs, and how these might 
interact with symptoms. In relation to the second question, 
we define the sense of self as an individual’s view of the 
distinctive features of their own character [14], and agency 
can be summarised briefly as having the ability to influence 
what happens in one’s life [15].
Methods
The systematic review was conducted in accordance 
with PRISMA (Preferred Reporting Items for Systematic 
Reviews) guidelines [16] (protocol available at: https ://
www.crd.york.ac.uk/PROSP ERO/displ ay_recor d.php?Recor 
dID=55646 . Registration number; 55646).
Eligibility criteria
Studies were included if they reported qualitative data about 
the experiences and views of people taking neuroleptic 
medication for a mental health condition and were written 
in English. Unpublished data were included and no date of 
publication range was specified. Studies only describing the 
views of clinicians or carers were not included.
Search
Repeated searches of the following electronic databases 
were conducted from inception of the project in 2017 until 
7 March 2019: Ovid MEDLINE, EMBASE, PsycINFO, 
PsycARTICLES, the Cochrane Library, CINAHL, Scopus 
and AMED. OpenGrey was also searched for unpublished 
literature. Hand searching of citations was also conducted. 
The following search terms were used: (“neuroleptic*” OR 
“atypical antipsychotic*” OR “neuroleptic*” OR “major 
tranquiliser*” OR “psychotropic*” OR “depot injec-
tion*” OR “psychiatric medication*”) AND (“attitude*” 
OR “experience*” OR “subjective*” OR “opinion*” OR 
“side-effect*” OR “complian*” OR “adheren*” OR “sat-
isfaction*” OR “perception*” OR “understanding*” OR 
“interpretation*” OR “view*” OR “tolerability*” OR “per-
spective*” OR “ insight*” OR “quality of life*” or “personal 
account*”).
Study selection
All titles and abstracts identified in the searches were 
screened to see whether they fulfilled eligibility criteria, and 
the full papers selected through this process were assessed 
by two reviewers (JT and JS). Queries about inclusion were 
resolved through consultation with two other reviewers (JM, 
RC).
Quality review
Study quality was assessed by two reviewers (JT and JS) 
using the Critical Appraisal Skills Programme (CASP) 
qualitative checklist [17]. The CASP was chosen since it 
is recommended by the Cochrane Collaboration [18] and 
is widely used in qualitative synthesis. Before commenc-
ing independent quality assessments, reviewers assessed the 
same five papers, with high interrater reliability (96%).
In line with recommendations for qualitative research 
synthesis, we did not set quality criteria for inclusion [19, 
20].
Data extraction, analysis and interpretation
All parts of the results and discussion sections of included 
papers that described or analysed study participants’ expe-
riences of taking neuroleptics were extracted and imported 
into the qualitative analysis software NVivo 11. We used 
thematic synthesis [20] to analyse this material (referred to 
in the process described below as ‘data’). Thematic synthe-
sis is an established method that uses the basic principles 
and practices of thematic analysis [21] to draw together key 
themes from across studies, and in so doing develop fur-
ther interpretations or new analytic insight [20]. Similar to 
thematic analysis, thematic synthesis offers a standardised 
but flexible approach that can be used to integrate relatively 
large numbers of qualitative studies and is recommended for 
topics in mental health [19].
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Our analysis proceeded as follows: Initially, the first 
reviewer (JT) and last reviewer (JM) read all the papers in 
detail to obtain an overview of the issues covered. Then 
the first reviewer coded the data from each of the papers 
line by line, with the second reviewer (JS) coding a sam-
ple of papers. The data were initially coded into descriptive 
themes, which directly described the findings of each of the 
included papers. Themes and sub-themes were collated in 
tables and a hierarchical descriptive tree, to compare and 
match themes across articles. This process went through 
several iterations with input from the whole research team. 
Descriptive themes were then grouped into analytic themes 
which were refined collaboratively through a further process 
of iteration. This step involves “going beyond the descriptive 
synthesis to produce a more conceptual line of argument” 
[19] (P 7). As with thematic analysis, we endeavoured to 
enhance validity through reflexive and collaborative work-
ing, in which we discussed and questioned theoretical and 
personal positions held by team members [22]. The detailed 
coding process, iterative consideration of descriptive and 
analytical themes and constant input of the whole research 
team ensured that there was strong consensus across the 
research team about the conceptualisation of themes and 
their relationships to the data.
Results
The search strategy identified 11,292 references. Of these, 
103 full text articles were assessed for eligibility and 69 
were excluded (see Fig. 1 for reasons for exclusion). A total 
of 35 studies were included in the review, including 34 pub-
lished studies and 1 unpublished doctoral thesis.
Study characteristics
Of the 35 included studies, participants were recruited from 
a variety of settings across 11 different countries, including 
inpatient facilities, community-based services, first episode 
psychosis services, general youth services and one was con-
ducted in a prison. Twenty-one studies were restricted to 
people with a diagnosis of schizophrenia, a psychotic disor-
der or bipolar disorder. One study included people with bor-
derline personality disorder and eight did not specify diag-
noses. Data were mainly collected via face to face interviews 
(N = 21) with other studies using a mixture of focus groups, 
interviews and diary entries (N = 8), questionnaires/surveys 
(N = 3) and data from Internet fora (N = 1) (see Table 1). One 
study explored the effects of clozapine specifically [23], and 
Fig. 1  Preferred Reporting 
Items For Systematic Reviews 
and Meta-Analyses (PRISMA) 
flow diagram
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one focused on the experience of taking depot medication 
exclusively [24]. Others involved people who were taking 
a variety of agents (see Table 1). Quality scores are shown 
in Table 1.
Themes (Table 2)
In the following analysis, we begin with how alterations 
to normal conscious experience, emotions, cognition and 
behaviour are described, in line with our first research ques-
tion. We then explore how the drugs impacted on symptoms 
of psychosis and other symptoms and problems. Overall, 
the first theme consists mainly of negative comments about 
neuroleptic-induced changes that were usually experienced 
as unpleasant. In comparison, descriptions of effects on 
symptoms are primarily positive. Themes 3 and 4 address 
our second research question and focus, respectively, on how 
neuroleptics affect people’s sense of self in both positive and 
negative ways, and on impacts on agency and how people 
perceive their level of control over the use of these drugs.
1. Neuroleptic-induced mental and behavioural alterations
‘The majority of participants spoke of feeling stu-
pefied, numb and slowed down, of being unable to 
interact in a normal fashion or undertake even modest 
activities, most wanting to sleep or lie down’ (pg S73) 
[25].
‘I remember taking my first depot… and it absolutely 
knocked me out… I couldn’t even lift a dustpan and 
brush in that I didn’t have any movement in my arms, 
in my legs… I didn’t have any thoughts in my head. I 
couldn’t do anything… I was like a zombie’ (pg 117) 
[26].
Across studies participants provided consistent descrip-
tions of a distinctive state produced by neuroleptics This 
generally consisted of lethargy, cognitive difficulties, 
dampened emotions and reduced motivation, which was 
associated with a variety of physical effects and could lead 
to impaired functioning. Participants in many studies com-
plained of feeling sedated and fatigued [4, 7, 8, 18, 19, 22, 
24–26] and highlighted the strength and unpleasantness 
of these effects using descriptions such as ‘dopey,’ [27] 
‘zonked,’ [28] feeling like a ‘cabbage’ [29] or ‘being hit 
by a truck’ [30]. These effects were summarised in one 
study as ‘crippling lethargy’ [31]. Associated with this 
were complaints of impaired cognitive function [23, 29, 
31–39], emotional blunting [31, 37, 38] and loss of moti-
vation [23, 26, 29, 30, 32, 35–37, 40], which were again 
described as profound and debilitating. Across studies, 
participants referred to feeling they had reduced clarity 
of thinking, intelligence, concentration and memory and 
felt ‘slowed down’ [31]. They referred to feeling ‘numbed 
out,’ [31] ‘empty’ [38], ‘lazy’ [36], being ‘less enthusi-
astic about life’ [35] and lacking ‘motivation and energy’ 
[41]. In some studies, these effects were associated with 
incapacitating physical effects including muscle weak-
ness, stiffness and tremor [23, 26, 28, 32, 33, 41]. Sexual 
dysfunction, particularly erectile dysfunction and loss of 
libido [23, 33, 34, 40], and weight gain [23, 27, 30, 31, 33, 
35–37, 40–43] were also common.
The negative impacts of these effects on the ability 
to function were often considerable [23, 27, 28, 36, 39, 
44–46]. They prevented people from having the motiva-
tion or physical capability to carry out simple tasks like 
brushing their teeth [39], using a dustpan and brush [26] 
or going shopping [34]. Participants in some studies men-
tioned how the effects of neuroleptics prevented them from 
working [27, 46]. In some studies it was noted that the 
experience of taking neuroleptics had made some people 
depressed, anxious or suicidal [27, 31, 32, 34, 36, 37]. 
Participants in ten studies explicitly compared the general 
state of physical, emotional and cognitive impairment that 
neuroleptics produced to being a ‘zombie’ [26, 28, 29, 31, 
32, 34, 37, 38, 42, 46].
2. Impact on symptoms
Table 2  Themes
Themes References Total
1. Global effects of neuroleptics [23, 25–52, 69–74] 35
2. Impact on symptoms [23, 26, 27, 29, 33–35, 37, 39, 40, 46, 47, 71, 74] 14
3. Medication and the self
(a) Depleting the self
[23, 30–33, 35–39, 41, 43, 72] 12
(b) Restoring the self [23, 26, 27, 34, 39] 5
(c) Symbolic effects [24, 28–30, 32–35, 38, 39, 44–46, 49, 51, 52] 16
4. Agency and medication [23–26, 28, 30–36, 38–44, 46–52, 70, 71, 74] 29
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‘I can see a change in my thinking, I used to have 
some…oh, you know, some funny thoughts… this 
medication helps me in a way that I can think…and see 
that it’s not right (thinking)…it has offered me hope 
again for a normal life’ (pg 148) [39].
‘Others described how the medication decreased the 
intensity, intrusiveness or emotional impact of psy-
chotic symptoms or unwelcome thoughts’ (pg 6) [37].
Despite the nature of drug-induced alterations, many par-
ticipants across studies felt that neuroleptics had helped to 
reduce symptoms and, as a consequence, improve their day 
to day life. Participants in numerous studies reported that the 
drugs decreased auditory hallucinations or ‘voices’ [23, 26, 
27, 33–35, 37, 46, 47]. In addition, three studies described 
how some participants felt that the medication improved 
their clarity of thinking [27, 34, 37] which was attributed 
in one study to reduced feelings of mental confusion [34].
Data in some studies provided an insight into how symp-
tom improvement might reflect the global effects induced by 
neuroleptics described above. In some studies, participants 
described how the cognitive and emotion blunting effects of 
neuroleptics interacted with symptoms in a beneficial way, 
acting as a ‘shield’ or a ‘glove’ to minimise the impact of 
psychotic experiences or beliefs [23, 35]. They described 
how the medication ‘slowed down’, ‘muffled’ or quietened 
voices [26, 34] or reduced symptoms or distress more gen-
erally [35, 40], as expressed in the idea that the medica-
tion ‘deadens things down’ [40]. A participant in one study 
described how the drugs helped by producing a ‘blockage 
of brain functions’ [23] and others expressed the idea that 
the medication acted as a protection against the intrusion of 
unwanted emotions or symptoms, acting as a ‘nice buffer 
between my anxiety/emotions and the outside world’ [37] 
and ‘giving my soul some protection’ [23].
Although there were more reports of sedative effects 
being unwelcome and unpleasant, participants in some stud-
ies reported that they valued the sedative effects of neuro-
leptics for their ability to increase sleep [23, 27, 33, 35, 37] 
and to produce feelings of calmness and relaxation [23, 26, 
27, 34, 37, 46]. These effects were especially evident in the 
study of clozapine [23]. In a number of studies, participants 
reported that neuroleptic medication improved the stabil-
ity of their mood and helped them to become more ‘level-
headed’ [23, 27, 33, 35, 37].
Data from several studies suggested that the symptom 
reduction achieved by neuroleptics appeared to improve 
people’s ability to function or ‘cope’ [46] and enabled some 
to lead a ‘fairly normal life’ [23, 27, 29, 34, 39, 46]. The 
authors of one study concluded that neuroleptics worked 
‘not by completely removing symptoms, but by calming the 
self and muffling the voices enough so that life was manage-
able and the person felt good.’ [34].
3. Medication and the self
(a) Depleting the self
‘A majority of these participants spoke specifically 
about the impairment to selfhood associated with psy-
chotropic drug use, such as damaged psychic connec-
tions to others and other losses of a spiritual nature’ 
(pg 48) [31].
‘It makes me fat, depressed, lethargic. It strips my life 
and soul’ (pg 163) [43].
Across studies, some participants identified how the gen-
eral alterations produced by neuroleptics affected their sense 
of self in a negative way, depriving them of valued aspects 
of their personality. The emotion-dampening effects of neu-
roleptics, their impact on motivation and initiative and the 
general dulling of cognitive capacities were particularly per-
ceived as producing unwanted changes [36, 37]. ‘Your mind 
changes and you think differently’ was how a participant 
from one study put it [39]. This made people feel as if they 
had lost their real selves: ‘I felt like a zombie. I did not feel 
like myself’ [38]. In addition, some people mentioned the 
loss of creativity [32, 33, 35, 37], imagination [41], humour 
[37] or a sense of ‘spirituality and spiritual connection’ [31]. 
They described how this altered their sense of who they were 
in a negative way, leading to ‘an impairment of selfhood,’ 
[31] or a loss of one’s ‘soul’ [43] or ‘spiritual nature’ [31]. 
One study concluded that the effects of neuroleptic medica-
tion disrupted people’s ‘emotional and perceptual being-in-
the-world,’ but also commented on how these effects could 
be difficult to separate from the individual’s ‘illness experi-
ence’ [34]. Drug-induced physical changes like weight gain 
[23, 30, 32, 35, 43] and sexual dysfunction [34, 40] were 
also discussed in terms of how they negatively affected peo-
ple’s sense of themselves and how they understood that they 
would be perceived by others.
(b) Restoring the self
On medication ‘the person felt in better control of him/
herself and recognised that she/he was functioning 
more and more like the old self’ (pg 135) [34].
‘When I started taking medication, I felt like a new 
man. I was taking [name of antipsychotic] and I was 
getting on with it, I felt really positive, I felt level-
headed’ (Y06) (pg 114) [26].
In contrast, a few participants in some studies identified 
how improvements in their mental symptoms produced by 
medication enabled them to regain a sense of self that had 
been negatively affected by their condition [26, 27, 34, 39]. 
People described feeling more like their ‘old self’ [34], a 
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‘new man’ [26], having hope of a ‘normal’ life and feeling 
like an ‘ordinary’ person again [39]. They described how, 
by enabling them to return to activities they enjoyed that 
were consistent with their underlying desires and values, 
neuroleptic medication enhanced their self-esteem [26] 
and helped them to feel ‘worthwhile’ [39]. Participants in 
some studies were reported as feeling that treatment had 
restored them to ‘normal,’ [23, 34], although the authors 
of one paper commented on how it was ‘only a few’ par-
ticipants that held this view [23]. However, it seems that 
for some people neuroleptics facilitated the repair of a 
previously disrupted sense of self.
(c) Symbolic effects
‘In this way, the act of continuously ingesting the 
medication makes the individual feel compelled 
to reaffirm and to acknowledge the schizophrenia. 
Therefore, due to being strongly linked, the medica-
tion can be as undesirable as the schizophrenia’ (pg 
367) [48].
‘I felt it was eroding of my self-image and when I took 
the medication it was more or less saying that I wasn’t 
whole’ (pg 150) [39].
Apart from the direct, pharmacological effects, taking 
neuroleptic medication also had a symbolic impact on peo-
ple’s sense of identity. For many people, the medication rep-
resented the fact that they were a patient with a disease. A 
few participants welcomed this view [30, 33, 34, 46, 49, 50]. 
Some others described how they had initially believed the 
medication represented a ‘cure’ for their disease, but later 
became disillusioned with this idea [30, 34, 35, 44], coming 
to see their previous beliefs in the possibility of a ‘miracle 
cure’ [34] as overly simplistic or ‘reductionist’ [30].
Participants from several studies expressed how they did 
not want to regard themselves as having ‘schizophrenia’ or a 
long-term condition and for these people, taking neuroleptic 
medication symbolised an unwanted and stigmatised identity 
as a chronic psychiatric patient [24, 29, 33, 38, 39, 44, 51, 
52]. They felt that needing to take medication made them 
‘lesser people’ [39] and confirmed to others that they were 
‘weird’ [24], ‘mad’ [44] or ‘crazy’ [38], especially because 
the effects of neuroleptics were sometimes very visible and 
described as making people ‘look ill’ [32] or ‘like a patient 
[29]. Neurological effects [28, 32, 39, 42, 45, 46] and weight 
gain [23, 39, 45] particularly contributed to this. There was 
a sense expressed in some studies that being regarded as 
needing medication denied the participants’ own intrinsic 
value, as if without treatment they were simply seen as the 
manifestation of a disease process and not a fully fledged 
person [34, 52]. A participant from one study expressed it 
as follows:
“They would think that the pill itself is what’s helping me 
be a person. And I mean, that’s not the case. Whether I 
took it or not, I still have value” [52].
4. Agency and medication
‘Several of the interviewees felt that they had no con-
trol over, or ability to influence, their drug treatment. 
There are many examples in the interviews of situa-
tions where the choices of drugs and doses were made 
by the psychiatrist without prior discussion with the 
person about former experiences of the drugs or of his 
or her own preferences’ (pg 824) [33].
‘I always accepted the medication. It may have made 
me feel bad, but I accepted it. I accepted it without 
complaint’ (P33) [48].
Many participants across studies appeared to have a 
passive attitude towards their medication that was often 
related to a broader sense of loss of agency. In some stud-
ies, for example, participants were noted to endure serious 
and unpleasant adverse effects without complaint, as if this 
was the normal, expected outcome of treatment [28, 48]. In 
several studies participants explained that they took medi-
cation simply because doctors told them to, and many felt 
they had no choice over it, nor did they understand what the 
medication was for or how it was meant to work [30–32, 36, 
39, 42, 47–49, 52]. The authors of one study commented 
that people who accepted neuroleptic medication were often 
unable to articulate exactly why they took it [31]. In vari-
ous studies, participants described feelings of hopelessness, 
helplessness, fear, confusion or indifference concerning their 
neuroleptic medication [28, 31, 33, 36, 48–50, 52].
Data from included studies also record how participants 
perceived their autonomy over medication to be restricted 
by assumptions about the underlying disorder, often report-
ing medication taking as necessary to avoiding a further 
relapse or rehospitalisation [23, 26, 30, 31, 35, 36, 40, 43, 
44, 51]. For some this involved having to ‘put up with side 
effects’ [42], but they concluded that taking the medication 
was ‘the lesser of two evils’ [38]. Others described broader 
social processes in which medication and reduced autonomy 
were related. Some were subject to formal legal controls, 
or felt that there was an informal threat of rehospitalisa-
tion if they did not accept medication [26, 31, 36, 42, 46, 
49]. Some described pressure from mental health profes-
sionals, relatives or friends [26, 31, 36, 39, 46], and some 
voiced concern about losing access to care and services if 
they refused medication [30, 46]. Across studies, partici-
pants also described the impediments to taking an active 
role in decisions about their treatment due to not being given 
161Social Psychiatry and Psychiatric Epidemiology (2020) 55:151–164 
1 3
information or opportunities to express their preferences [26, 
30–33, 36, 38, 39, 42, 43, 46, 47, 49, 52].
These effects combined to produce what some studies 
termed a ‘resigned’ or ‘reluctant’ acceptance of medication 
[28, 36]. Some participants had ‘given up’ trying to exert an 
influence over their treatment and a state of passive endur-
ance had become a ‘pervading way of life’ for many peo-
ple [28]. However, passive acceptance was not ubiquitous: 
many studies also reported some participants who actively 
embraced taking neuroleptic medication, and described con-
tributing to decisions about their treatment in the context 
of a positive and collaborative relationship with their clini-
cians [24, 26, 30, 33, 34, 36, 42, 43, 47–51]. Others actively 
resisted the expectations of professionals and asserted their 
autonomy over their medication either by discontinuing it 
altogether [26, 30, 31, 34, 42, 43, 46, 48, 51], or by modify-
ing the regime to suit their needs [26, 28, 33, 36, 45, 46].
Discussion
The current paper synthesises data from the increasing 
number of studies of people’s experiences of neuroleptic 
medications. Users of neuroleptics consistently described 
a distinctive experience characterised by sedation, cogni-
tive impairment, emotional blunting and reduced motiva-
tion, which was associated with a variety of physical effects, 
including neurological effects, weight gain and sexual dys-
function. These effects are also documented in non-clini-
cal samples [53]. They have been referred to in the past as 
‘neuroleptic-induced deficit’ syndrome [54], ‘neuroleptic 
dysphoria’ [55] and ‘deactivation syndrome’ [56], and they 
have been linked with negative effects on quality of life 
[55]. Harsher critics suggest neuroleptic effects represent a 
form of chemical modification of behaviour and personal-
ity [56, 57]. In the current study, the effects of neuroleptics 
were reported to interfere with people’s ability to carry out 
basic activities, but they were also associated with benefi-
cial effects on the symptoms of psychosis and some other 
symptoms such as anxiety and insomnia. When medication 
reduced the intensity of intrusive psychotic experiences and 
other symptoms, it was able to improve people’s ability to 
function and restore a sense of normality. Others found the 
mental restriction and physical alterations hard to bear, and 
experienced a loss of important aspects of their sense of self 
and agency.
The data therefore provide some support for suggestions 
that dampening of emotional responses and slowing of cog-
nitive processes may explain the ability of neuroleptic drugs 
to reduce psychotic symptoms [8, 9, 58]. Some authors have 
suggested that the therapeutic emotional effects of neuro-
leptics are mediated through the dopamine system [10], but 
the fact that neuroleptics have varying effects on many other 
neurotransmitter systems that affect arousal, cognition and 
emotion (noradrenaline and serotonin, for example) [59, 
60] suggests that the origins of these effects may be more 
complex.
Anything that changes our mental faculties is likely to 
impact on our sense of ourselves, and this is a common 
experience in relation to mood or experience-modifying 
agents [11]. In the studies we reviewed, some participants 
felt neuroleptic-induced effects deprived them of impor-
tant aspects of their personality; their drives, imagination 
or humour, for example. Others felt that by reducing the 
symptoms of psychosis, the drugs were able to restore them 
to a state in which they felt ‘themselves’ again. Similarly, 
some people were content to view themselves as having a 
disease requiring ongoing treatment, while others felt that 
taking neuroleptic medication symbolised a tainted identity. 
Schizophrenia or psychosis can disrupt people’s sense of self 
[61, 62], and studies of personal recovery have described the 
importance of reconstructing a sense of self [63] in a way 
that is distinct from symptom improvement [64]. Therefore, 
although neuroleptics may effectively suppress symptoms, 
their effects can nevertheless be experienced as detrimental 
to sense of self and identity, with important implications for 
social functioning and achievement of life goals.
Several studies, including some of those included in this 
review, have commented on the loss of autonomy expe-
rienced by people with severe mental disorder, and their 
relative lack of involvement in decision-making compared 
to patients with other medical conditions [36, 46, 65]. In 
the current review, this was due to the ongoing or recur-
rent nature of the underlying condition, legal restrictions, 
informal pressures from family, friends or professionals, 
or lack of encouragement by clinicians to be involved in 
treatment decisions. The passivity and occasional indiffer-
ence described in several studies may also reflect the effects 
of neuroleptics on energy and motivation, or might alter-
natively be a manifestation of the negative symptoms of 
schizophrenia in some cases. A previous systematic review 
also highlighted loss of autonomy in neuroleptic users, iden-
tifying this as occurring in relation to early treatment of the 
acute stages of the condition, and suggesting that people 
regain a sense of agency as their condition stabilises [13]. In 
contrast, the current review found that across studies, there 
appeared to be a group of people who had fallen into a long-
term state of passivity and hopelessness in relation to their 
neuroleptic medication.
Limitations
The included studies were diverse in their settings and popu-
lations studied, but most were conducted in Western coun-
tries and studies not published in English were not included. 
Therefore, findings may not generalise to other parts of the 
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world. The quality of the papers was generally high, but 
studies employed diverse methods of data collection and 
analysis and the aims and focus of different studies also var-
ied. Given the variety of populations and the consistency of 
results, the analysis suggests that the included studies pro-
vide a reasonably representative view of the typical experi-
ence of taking neuroleptic medication.
Qualitative methods of systematic reviewing are still rela-
tively new [20], but thematic synthesis facilitates the analy-
sis of a relatively large number of studies, and allows for a 
broad summary of the literature. The collaborative nature of 
the current analysis through the various iterations ensured 
that the themes were firmly grounded in the data.
Clinical implications
Clinicians have been found to underestimate the impact 
of the adverse effects of neuroleptics on patients’ quality 
of life [66, 67], which may contribute to the difficulties of 
achieving a more collaborative approach to decision-mak-
ing with people with severe mental disorders [65, 68]. A 
fuller understanding of how neuroleptic drugs impact on 
important aspects of people’s experience and feelings about 
themselves, and how these effects are entwined with effects 
on symptoms will enable clinicians to better recognise and 
respond to patients’ concerns. This can facilitate better col-
laboration and improve clinicians’ ability to support patients 
to retain agency and make informed decisions about their 
drug treatment based on balancing the benefits of neurolep-
tic drugs against the unwanted changes they can produce.
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